Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada

Geneviève Deceuninck; Nicholas Brousseau; Brigitte Lefebvre; Caroline Quach; Bruce Tapiero; Yen-Giang Bui; Michaël Desjardins; Philippe De Wals

doi:10.1016/j.vaccine.2023.07.049

Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada

Vaccine. 2023 Aug 31;41(38):5486-5489. doi: 10.1016/j.vaccine.2023.07.049. Epub 2023 Jul 29.

Authors

Geneviève Deceuninck¹, Nicholas Brousseau², Brigitte Lefebvre³, Caroline Quach⁴, Bruce Tapiero⁵, Yen-Giang Bui⁶, Michaël Desjardins⁷, Philippe De Wals⁸

Affiliations

¹ Centre de recherche du Centre hospitalier universitaire de Québec, Équipe de recherche en vaccination, Québec, QC, Canada; Institut National de Santé Publique du Québec, Direction des risques biologiques, Québec, QC, Canada. Electronic address: genevieve.deceuninck.ciussscn@ssss.gouv.qc.ca.
² Centre de recherche du Centre hospitalier universitaire de Québec, Équipe de recherche en vaccination, Québec, QC, Canada; Institut National de Santé Publique du Québec, Direction des risques biologiques, Québec, QC, Canada.
³ Institut national de santé publique du Québec, Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC, Canada.
⁴ Department of Microbiology, Infectious Diseases and Immunology, University of Montreal, Montreal, QC, Canada; Division of Medical microbiology, Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montreal, QC, Canada.
⁵ Service des maladies infectieuses, CHU Sainte-Justine, Montréal, QC, Canada.
⁶ Institut National de Santé Publique du Québec, Direction des risques biologiques, Québec, QC, Canada.
⁷ Department of Microbiology, Infectious Diseases and Immunology, University of Montreal, Montreal, QC, Canada; Division of Infectious Diseases, Centre hospitalier de l'Université de Montréal, Qc, Canada.
⁸ Centre de recherche du Centre hospitalier universitaire de Québec, Équipe de recherche en vaccination, Québec, QC, Canada; Institut National de Santé Publique du Québec, Direction des risques biologiques, Québec, QC, Canada; Département de Médecine Sociale et Préventive, Université Laval, Québec, QC, Canada; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.

PMID: 37524629
DOI: 10.1016/j.vaccine.2023.07.049

Abstract

In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7 was replaced by PCV10 in 2009, by PCV13 in 2011 and by PCV10 in 2018, without catch-up in all instances. The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness with the number of doses. PCV13 protection against serotype 3 IPD seems to be short-lived.

Keywords: Children; Invasive pneumococcal disease; Pneumococcal conjugated vaccine; Serotype-3; Vaccine effectiveness.

MeSH terms

Canada
Child
Heptavalent Pneumococcal Conjugate Vaccine
Humans
Infant
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines
Quebec / epidemiology
Serogroup
Streptococcus pneumoniae*
Vaccines, Conjugate

Substances

Vaccines, Conjugate
Heptavalent Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines